Annual FCF
-$162.80 M
-$35.83 M-28.22%
December 31, 2024
Summary
- As of March 12, 2025, KROS annual free cash flow is -$162.80 million, with the most recent change of -$35.83 million (-28.22%) on December 31, 2024.
- During the last 3 years, KROS annual FCF has fallen by -$99.63 million (-157.71%).
- KROS annual FCF is now -2485.35% below its all-time high of $6.83 million, reached on December 31, 2018.
Performance
KROS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$46.30 M
-$15.41 M-49.90%
December 31, 2024
Summary
- As of March 12, 2025, KROS quarterly free cash flow is -$46.30 million, with the most recent change of -$15.41 million (-49.90%) on December 31, 2024.
- Over the past year, KROS quarterly FCF has stayed the same.
- KROS quarterly FCF is now -2841.36% below its all-time high of -$1.57 million, reached on March 31, 2022.
Performance
KROS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$162.80 M
-$20.30 M-14.24%
December 31, 2024
Summary
- As of March 12, 2025, KROS TTM free cash flow is -$162.80 million, with the most recent change of -$20.30 million (-14.24%) on December 31, 2024.
- Over the past year, KROS TTM FCF has stayed the same.
- KROS TTM FCF is now -6378.31% below its all-time high of -$2.51 million, reached on March 31, 2019.
Performance
KROS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
KROS Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.2% | 0.0% | 0.0% |
| 3 y3 years | -157.7% | -134.7% | -157.7% |
| 5 y5 years | -900.7% | -739.3% | -900.7% |
KROS Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -157.7% | at low | -2841.4% | at low | -201.3% | at low |
| 5 y | 5-year | -900.7% | at low | -2841.4% | at low | -900.7% | at low |
| alltime | all time | -2485.3% | at low | -2841.4% | at low | -6378.3% | at low |
Keros Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$162.80 M(+28.2%) | -$46.30 M(+49.9%) | -$162.80 M(+14.2%) |
| Sep 2024 | - | -$30.89 M(-23.0%) | -$142.50 M(-2.5%) |
| Jun 2024 | - | -$40.11 M(-11.9%) | -$146.15 M(+6.5%) |
| Mar 2024 | - | -$45.51 M(+75.0%) | -$137.18 M(+8.0%) |
| Dec 2023 | -$126.97 M(+78.1%) | -$26.00 M(-24.7%) | -$126.97 M(+3.4%) |
| Sep 2023 | - | -$34.53 M(+10.9%) | -$122.77 M(+8.6%) |
| Jun 2023 | - | -$31.14 M(-11.8%) | -$113.01 M(+7.6%) |
| Mar 2023 | - | -$35.30 M(+62.0%) | -$105.03 M(+47.3%) |
| Dec 2022 | -$71.30 M(+12.9%) | -$21.79 M(-12.0%) | -$71.30 M(+3.0%) |
| Sep 2022 | - | -$24.78 M(+7.0%) | -$69.23 M(+17.3%) |
| Jun 2022 | - | -$23.16 M(+1371.2%) | -$59.04 M(+9.3%) |
| Mar 2022 | - | -$1.57 M(-92.0%) | -$54.03 M(-14.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$63.17 M(+69.9%) | -$19.72 M(+35.2%) | -$63.17 M(+22.7%) |
| Sep 2021 | - | -$14.59 M(-19.6%) | -$51.50 M(+7.7%) |
| Jun 2021 | - | -$18.15 M(+69.4%) | -$47.80 M(+20.7%) |
| Mar 2021 | - | -$10.71 M(+33.1%) | -$39.61 M(+6.5%) |
| Dec 2020 | -$37.19 M(+128.6%) | -$8.05 M(-26.0%) | -$37.19 M(+7.3%) |
| Sep 2020 | - | -$10.89 M(+9.4%) | -$34.65 M(+29.3%) |
| Jun 2020 | - | -$9.96 M(+20.0%) | -$26.80 M(+21.5%) |
| Mar 2020 | - | -$8.30 M(+50.4%) | -$22.05 M(+35.5%) |
| Dec 2019 | -$16.27 M(-338.4%) | -$5.52 M(+81.6%) | -$16.27 M(+51.3%) |
| Sep 2019 | - | -$3.04 M(-41.6%) | -$10.75 M(+39.4%) |
| Jun 2019 | - | -$5.20 M(+107.0%) | -$7.72 M(+207.0%) |
| Mar 2019 | - | -$2.51 M | -$2.51 M |
| Dec 2018 | $6.83 M | - | - |
FAQ
- What is Keros Therapeutics annual free cash flow?
- What is the all time high annual FCF for Keros Therapeutics?
- What is Keros Therapeutics annual FCF year-on-year change?
- What is Keros Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Keros Therapeutics?
- What is Keros Therapeutics quarterly FCF year-on-year change?
- What is Keros Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Keros Therapeutics?
- What is Keros Therapeutics TTM FCF year-on-year change?
What is Keros Therapeutics annual free cash flow?
The current annual FCF of KROS is -$162.80 M
What is the all time high annual FCF for Keros Therapeutics?
Keros Therapeutics all-time high annual free cash flow is $6.83 M
What is Keros Therapeutics annual FCF year-on-year change?
Over the past year, KROS annual free cash flow has changed by -$35.83 M (-28.22%)
What is Keros Therapeutics quarterly free cash flow?
The current quarterly FCF of KROS is -$46.30 M
What is the all time high quarterly FCF for Keros Therapeutics?
Keros Therapeutics all-time high quarterly free cash flow is -$1.57 M
What is Keros Therapeutics quarterly FCF year-on-year change?
Over the past year, KROS quarterly free cash flow has changed by $0.00 (0.00%)
What is Keros Therapeutics TTM free cash flow?
The current TTM FCF of KROS is -$162.80 M
What is the all time high TTM FCF for Keros Therapeutics?
Keros Therapeutics all-time high TTM free cash flow is -$2.51 M
What is Keros Therapeutics TTM FCF year-on-year change?
Over the past year, KROS TTM free cash flow has changed by $0.00 (0.00%)